Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

200
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
200
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

395
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
395
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

242
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
242

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

Journal of Crohn's & colitis·2026
Same author

Transmural healing is significantly associated with prevention of clinical relapse in Crohn's disease.

Inflammatory bowel diseases·2026
Same author

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Pain, pain catastrophizing, and autonomic nervous system dysfunction after traumatic injury: A prospective cohort study.

The journal of pain·2026
Same author

Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease.

Intestinal research·2026
Same author

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.

Journal of gastroenterology and hepatology·2026
Same journal

Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomised Trial of Rifaximin for Covert Hepatic Encephalopathy.

Alimentary pharmacology & therapeutics·2026
Same journal

Editorial: Dissecting the Natural History of Recurrent Pancreatitis.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: HBsAg Loss After COVID-19 Vaccination: Implications for HBV Screening, Immunity Monitoring, and Health Worker Protection in LMICs. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same journal

Editorial: Mind the Gap-Peripheral Immune Signatures of HBV Cirrhosis in an Underserved Population.

Alimentary pharmacology & therapeutics·2026
Same journal

Editorial: Fatigue in Disorders of Gut-Brain Interaction-An Important Symptom to Recognise.

Alimentary pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Sep 16, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.4K

Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.

John David Chetwood1,2, Arteen Arzivian3, Yvonne Tran3

  • 1Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.

Alimentary Pharmacology & Therapeutics
|July 11, 2025
PubMed
Summary
This summary is machine-generated.

Subcutaneous infliximab shows high efficacy in inflammatory bowel disease (IBD), potentially offering greater clinical benefits than intravenous formulations. This suggests confidence in its use for IBD patients, though further trials are recommended.

Keywords:
inflammatory bowel diseaseinfliximabsubcutaneous

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K
Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.2K

Related Experiment Videos

Last Updated: Sep 16, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.4K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K
Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.2K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Subcutaneous infliximab offers potential advantages over intravenous formulations for inflammatory bowel disease (IBD).
  • Uncertainty exists regarding the comparative efficacy of subcutaneous versus intravenous infliximab in IBD management.
  • Assessing treatment efficacy is crucial for optimizing patient outcomes in IBD.

Purpose of the Study:

  • To conduct a systematic review and network meta-analysis comparing the efficacy of subcutaneous and intravenous infliximab in IBD patients.
  • To evaluate clinical response, clinical remission, and endoscopic remission at 30 and 54 weeks.
  • To provide evidence-based insights for clinical decision-making regarding infliximab formulations in IBD.

Main Methods:

  • Systematic review and network meta-analysis of published studies up to August 2024.
  • Inclusion of 9 studies involving 2519 patients with Crohn's disease and ulcerative colitis.
  • Comparative efficacy assessment using Surface Under the Cumulative Ranking Curve (SUCRA), posterior probability modeling, and contrast plots.

Main Results:

  • Subcutaneous infliximab ranked highest in overall efficacy across comparisons based on SUCRA analysis.
  • Strong evidence suggests subcutaneous infliximab superiority for clinical response at 30 weeks and clinical remission at 30 and 54 weeks.
  • Moderate evidence supported clinical response at 54 weeks; no significant difference was found for endoscopic remission at 54 weeks.

Conclusions:

  • Subcutaneous infliximab demonstrates high efficacy rates and potential clinical benefits in IBD patients.
  • The findings support the use of subcutaneous infliximab in IBD, offering confidence to patients and clinicians.
  • Further head-to-head trials are necessary to definitively confirm the relative efficacy between subcutaneous and intravenous infliximab formulations.